Elite in Waldenstrom Macroglobulinemia

Christian Buske

Albert Einstein Allee 11, 
Ulm, BW, DE 
Elite in Waldenstrom Macroglobulinemia
Albert Einstein Allee 11, 
Ulm, BW, DE 
OverviewLocationsClinical Research

Overview

Christian Buske practices in Ulm, Germany. Mr. Buske is rated as an Elite expert by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Waldenstrom Macroglobulinemia, Follicular Lymphoma, Non-Hodgkin Lymphoma, Tissue Biopsy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 175 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 54 articles and participated in 2 clinical trials in the study of Waldenstrom Macroglobulinemia.

Gender
Male

Locations

Albert Einstein Allee 11, Ulm, BW 89081, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)
Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)
Enrollment Status: Active_not_recruiting
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Obinutuzumab
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3
Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Enrollment Status: Completed
Publish Date: May 13, 2024
Intervention Type: Drug
Study Drugs: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
Study Phase: Phase 3
View 2 Less Clinical Trials

175 Total Publications

Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia.
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia.
Journal: Seminars in hematology
Published: June 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Buske's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile